SCHEMBL6740869

SCHEMBL6740869

CC(C)n1ncc2ccc(CCOS(C)(=O)=O)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.38
HDAC8 Q9BY41 1/20 0.37
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE1C Q14123 1/20 0.35
PTGER3 P43115 1/20 0.34
ACLY P53396 1/20 0.33
PTGS2 P35354 1/20 0.32
CACNA1H O95180 1/20 0.32
HTR2A P28223 4/20 0.32
HTR2C P28335 4/20 0.32
HTR2B P41595 3/20 0.32
HTR1A P08908 2/20 0.30
ADRA2A P08913 2/20 0.30
ADRA2B P18089 2/20 0.30
ADRA2C P18825 2/20 0.30
KDM2B Q8NHM5 1/20 0.30
KDM4C Q9H3R0 1/20 0.30
HTR1D P28221 1/20 0.30
HTR7 P34969 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740873 0.79 KMO (0.39) KMOPDE1APDE1BPDE1CCACNA1H
SCHEMBL31638076 0.76 CTNNB1 (0.51) PDE1CCACNA1HHTR2ACTNNB1TCF7
SCHEMBL12327554 0.75 HDAC8 (0.53) KMOHDAC8PDE1APDE1BPDE1C
SCHEMBL6743454 0.75 HRH3 (0.39) KMOHDAC8PDE1APDE1BPDE1C
SCHEMBL15687398 0.74 KMO (0.45) KMOHDAC8PDE1APDE1BPDE1C
SCHEMBL20942425 0.74 HDAC8 (0.43) KMOHDAC8PDE1APDE1BPDE1C
SCHEMBL30174486 0.74 KMO (0.45) KMOHDAC8PDE1APDE1BPDE1C
SCHEMBL6740845 0.73 HRH3 (0.40) KMOHDAC8PDE1APDE1BPDE1C
SCHEMBL6739776 0.72 KMO (0.53) KMOHDAC8PDE1APDE1BPDE1C
SCHEMBL6746545 0.71 SIGMAR1 (0.48) HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-08-26 US disclosed
US-6716837-B1 INDOLE AND INDAZOLE COMPOUNDS NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-04-06 US disclosed
EP-1196380-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2002-04-17 EP disclosed
WO-2001005758-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS ALLELIX CORP. (CA) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine SCN7A, CNR2, HTR7 KMO 453/4885HDAC8 428/4885PDE1A 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.